Fernando Torres Andón is an AECC Researcher in the Nanomedicine for Cancer Immunotherapy department at the CiMUS, University of Santiago de Compostela, Spain. He is a pharmacist with a PhD in Molecular Biology, a postdoc in Nanotoxicology with Prof. Bengt Fadeel at Karolinska Institutet, Sweden, and a postdoc in Tumor Immunology with Prof. Paola Allavena at the Humanitas Institute, Italy. His current research at Alonso's lab (CiMUS) is focused on the development and evaluation of new nanostructures for the targeting and reprograming of tumor-associated macrophages into antitumor macrophages, with the ability to kill tumor cells, inhibit angiogenesis and promote adaptive immune responses in solid tumors, with the ultimate goal of providing new solutions for patients with cancer.